PHASE I/II STUDY LADARIXIN AND SOTORASIB IN ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER (NSCLC). | NYU Langone Health

Go Back to All Clinical Trials

PHASE I/II STUDY LADARIXIN AND SOTORASIB IN ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER (NSCLC).

Brief description of study

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in subjects with advanced KRAS G12C mutant NSCLC.

Clinical Study Identifier: s22-00959

ClinicalTrials.gov Identifier: NCT05815173